A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered KT-253 in Adult Patients With High Grade Myeloid Malignancies and Acute Lymphocytic Leukemia, Lymphoma and Advanced Solid Tumors KT-253

What's the purpose of this trial?

This Phase 1 study will evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD), and clinical activity of KT-253 in adult patients with relapsed or refractory (R/R) high grade myeloid malignancies, acute lymphocytic leukemia (ALL), R/R lymphoma, and R/R solid tumors. The study will identify the pharmacologically optimal dose(s) of KT-253 as the recommended Phase 2 dose (RP2D), based on all safety, PK, PD, and efficacy data.

This trial is currently open and accepting patients.


What will happen during the trial?

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

Inclusion Criteria:

1. All Participants:

* Eastern Cooperative Oncology Group performance status: 0-2.
* Resolved acute effects of any prior therapy except for alopecia to baseline severity or Grade ≤1 NCI CTCAE and Grade ≤2 neuropathy
* Adequate organ function at screening
2. Solid Tumors and Lymphoma (Arm A) ONLY

* Histologically or pathologically confirmed solid tumor or lymphoma.
* Relapsed and/or refractory (R/R) disease to at least two prior standard-of-care treatments or tumors for whom standard therapies are not available.
3. Advanced high grade myeloid malignancies, and Acute Lymphocytic Leukemia (Arm B) ONLY

* Primary diagnosis of AML, ALL, High/Very High-risk MDS, MDS/MPN. Must be relapsed/refractory to standard therapies.

Exclusion Criteria:

1. All Participants:

* Ongoing unstable cardiovascular function.
* Major surgery requiring general anesthesia within 4 weeks prior to first dose of study drug.
* History of or active concurrent malignancy unless disease-free for ≥ 2 years.
* Exposures to anticancer therapy within 2 weeks or 5 half-lives whichever is shorter; or 4 weeks from any biologics/immunotherapies or any investigational therapy prior to the first dose of study drug.
* Known presence of p53 mutation in tumor tissue
2. Solid Tumors and Lymphoma (Arm A) ONLY

* Known active uncontrolled or symptomatic central nervous system (CNS) metastases.
* Autologous or allogenic hematopoietic stem cell transplant (HSCT) within six months prior to first dose of study drug or participant has progressed within six months from the day of stem cell infusion (for lymphoma participants only).
3. Advanced high grade myeloid malignancies, and ALL (Arm B) ONLY

* Active CNS leukemia. Participants with symptoms suggestive of CNS disease will require a lumbar puncture to rule out CNS disease.
* Prior chemotherapy/radiation (including craniospinal radiation) within 2 weeks prior to the first dose of study drug.
* Received allogeneic hematopoietic cell transplantation (HCT) \<12 weeks prior to first dose or donor lymphocyte infusion (DLI) without conditioning \<4 weeks prior to first dose.
* Received autologous stem cell transplant (ASCT) \< 4 weeks prior to first dose or the patient has not recovered from transplant associated toxicities to ≤ grade 1 prior to the first dose of study drug.
* Received chimeric antigen receptor therapy or other modified T cell therapy \<3 weeks prior to the first dose.
* Patients with signs or symptoms of Grade ≥ 2 acute or chronic graft versus host disease (GVHD) within 2 weeks of enrollment.

Additional Trial Information

Phase 1

Enrollment: 70 patients (estimated)

View More

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.

Arizona

HonorHealth Research and Innovation Institute

Scottsdale, AZ

Open and Accepting

California

University of California Davis Comprehensive Cancer Center

Sacramento, CA

Open and Accepting

Massachusetts

Dana-Farber Cancer Institute (Main)

Boston, MA

Open and Accepting

Michigan

Henry Ford Hospital

Detroit, MI

Open and Accepting

New York

Montefiore Medical Center (Moses Campus)

The Bronx, NY

Open and Accepting

Oklahoma

OU Health Stephenson Cancer Center

Oklahoma City, OK

Open and Accepting

Texas

Mary Crowley Cancer Research

Dallas, TX

Open and Accepting

MD Anderson Cancer Center The University of Texas

Houston, TX

Open and Accepting

Virginia

Inova Schar Cancer Institute

Fairfax, VA

Open and Accepting
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message